Author: Galeotti, Caroline; Kaveri, Srini V; Bayry, Jagadeesh
Title: Intravenous immunoglobulin immunotherapy for coronavirus diseaseâ€19 (COVIDâ€19) Cord-id: 7muey1nh Document date: 2020_10_16
ID: 7muey1nh
Snippet: Intravenous immunoglobulin (IVIG), a pooled normal IgG from several thousand healthy donors and one of the commonly used immunotherapeutic molecules for the management of autoimmune and inflammatory diseases, has been explored for the treatment of coronavirus diseaseâ€19 (COVIDâ€19). Although placeboâ€controlled, doubleâ€blind randomised clinical trials are lacking, current data from either retrospective, case series or openâ€label randomised controlled trials provide an indicator that IVIG
Document: Intravenous immunoglobulin (IVIG), a pooled normal IgG from several thousand healthy donors and one of the commonly used immunotherapeutic molecules for the management of autoimmune and inflammatory diseases, has been explored for the treatment of coronavirus diseaseâ€19 (COVIDâ€19). Although placeboâ€controlled, doubleâ€blind randomised clinical trials are lacking, current data from either retrospective, case series or openâ€label randomised controlled trials provide an indicator that IVIG immunotherapy could benefit severe and critically ill COVIDâ€19 patients. See alsoShao et al. [Image: see text]
Search related documents:
Co phrase search for related documents, hyperlinks ordered by date